ArticleBMC infectious diseases2025
Predictive value of combined inflammatory markers for septic cardiomyopathy: a retrospective study.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Integrated bioinformatics analysis reveals cross-talking hub genes and therapeutic agents between sepsis and acute myocardial infarction.Annals of medicine · 2026Article
- miR-454-3p alleviates LPS-induced cardiomyocyte damage by negatively regulating STAT3 in sepsis-induced cardiomyopathy.Internal and emergency medicine · 2026Article
- Early Predictive Value of Peripheral Inflammatory Index Combined with High-Sensitivity Troponin T for Sepsis-Induced Cardiomyopathy.Mediterranean journal of hematology and infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSeptic cardiomyopathy (SCM) is a common but underdiagnosed complication of sepsis characterized by acute myocardial dysfunction driven by inflammatory and immune dysregulation. This study aimed to investigate the clinical characteristics, inflammatory profiles, and predictive markers associated with SCM, highlighting its diagnostic and prognostic importance.
methodsClinical data from 89 controls and 71 SCM patients were retrospectively analyzed from January 2022 to July 2024. The differences in demographics, clinical characteristics, hematological parameters, inflammatory markers, and cardiac injury markers were compared between the two groups. Additionally, the risk factors for SCM were evaluated via univariate and multivariate logistic regression analyses. After that, the predictive capacity of each marker for SCM was assessed through the receiver operating characteristics curve analysis.
resultsThe SCM group had significantly higher levels of SOFA score, platelet-to-lymphocyte ratio (PLR), cardiac troponin I (cTnI), neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index, NT-proBNP, and inflammatory markers such as CRP, TNF-α, PCT, and IL-6 (P < 0.05). Multivariate analysis revealed that cTnI (OR = 4.548, 95% CI: 1.164–19.452, P = 0.041), NLR (OR = 4.231, 95% CI: 2.443–7.328, P < 0.001), and CRP (OR = 1.138, 95% CI: 1.061–1.221, P < 0.001) were independent risk factors for SCM. The combined use of NLR, PLR, and CRP yielded an AUC of 0.962, with a sensitivity of 91.5% and specificity of 93.3%.
conclusionsSCM is associated with pronounced inflammatory activation and myocardial injury. This study identifies cTnI, NLR, and CRP as independent risk factors. Notably, the combined use of NLR, CRP, and PLR significantly enhances diagnostic accuracy, providing a reliable basis for early identification and targeted intervention in SCM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.